Compound ID | 158
Synonym(s): TG-873870 (Taigexyn)
Class: Quinolone
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | DNA synthesis inhibitor. Inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting bacterial DNA replication. |
| Target Pathogen: | Staphylococcus aureus (MSSA, MRSA and selected resistant phenotypes), Staphylococcus epidermidis, Streptococcus pneumoniae (including penicillin- and fluoroquinolone-resistant isolates), Enterococcus faecalis, Enterococcus faecium (including VRE), Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii, Haemophilus influenzae, Neisseria gonorrhoeae, Helicobacter pylori, Chlamydia trachomatis and Chlamydia pneumoniae. |
| Combined with other compounds: | Yes |
| Propensity to select resistant mutants: | Low |
| Description: | Synthetic, non-fluorinated quinolone antibacterial developed in oral and intravenous formulations; approved as nemonoxacin malate (Taigexyn®) in Taiwan and subsequently in China. |
| Institute where first reported: | Procter & Gamble Pharmaceuticals |
| Year first mentioned: | 2001 |
| Highest development stage: | Approved |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/11993740 |
| Guide to Pharmacology: | nemonoxacin |
| Citations: |
|
| Patents: |
|